Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp53 | Acromegaly and GH | ECE2019

Efficacy and safety of once-weekly somapacitan in adult growth hormone deficiency (AGHD) confirmed in a 53-week REAL-1 trial extension

Johannsson Gudmundur , Gordon Murray , Rasmussen Michael Hojby , Hakonsson Ida Holme , Svaerke Claus , Tahara Shigeyuki , Takano Koji , Biller Beverly MK

Background: Following the 34-week, double-blind, placebo-controlled main phase of REAL-1 (NCT02229851), this open-label trial extension evaluated efficacy and safety of somapacitan in patients aged 23–79 years with AGHD, for an additional 52 weeks (8 weeks’ dose titration followed by 44 weeks’ fixed dose treatment; 86 weeks’ treatment in total).Methods: Patients completing the main trial entered the extension: 1) somapacitan-treated p...

ea0081p415 | Pituitary and Neuroendocrinology | ECE2022

Effects of somapacitan on glucose metabolism in adults with GH deficiency

Johannsson Gudmundur , MK Biller Beverly , Fukuoka Hidenori , Ho Ken , Hojby Rasmussen Michael , Nedjatian Navid , Svaerke Claus , CJ Yuen Kevin , Takahashi Yutaka

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...